Technology Listings


16 Results Sort By:
Combination Therapy to Treat Pediatric Brain Tumor
Application Combination therapy (inhibition of STAT3 and YB-1) to treat medulloblastoma. Key Benefits Drug combination targets cancer stem cells. Increased apoptosis of cancer cells compared to current chemotherapeutic agents. Market Summary Medulloblastoma (MB) is the most common cancerous brain tumor that affects children and survival rates...
Published: 1/28/2020       Inventor(s): Tobey MacDonald, Anna Kenney, James Felker, Abhinav Dey
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries. Key Benefits Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries. Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 12/2/2019       Inventor(s): Ahsan Husain, Nawazish Naqvi
Targeted Anti-Cancer Nanoparticle Therapy
Application A drug-carrying nanoparticle that selectively targets cancer cells. Key Benefits Incorporates an already proven anti-cancer therapeutic. Increases deliverability. Targets cancer cells. Market Summary Tris DBA palladium has been shown to have anti-cancer activity against melanoma and pancreatic cancer. However, Tris DBA has not...
Published: 9/9/2019       Inventor(s): Jack Arbiser, Lily Yang
Antibody for the Treatment of Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Application Repurposed monoclonal antibody (mAb) that blocks inflammatory CD4 T cell migration for the treatment of NASH and liver fibrosis. Key Benefits Therapy for treating NASH, NAFLD, and liver fibrosis. Potential reduced approval time due to existing clinical safety data for α4β7 mAb. Market Summary Non-alcoholic steatohepatitis...
Published: 6/24/2019       Inventor(s): Frank Anania, Khalidur Rahman
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 6/18/2019       Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
PLK1 Inhibitors for the Diagnosis and Treatment of Small Cell Lung Carcinoma (SCLC)
Application Polo Like Kinase 1 (PLK1) inhibitor as a potent treatment strategy for SCLC patients with a specific TP53 mutation. Key Benefits A personalized cell therapy for recurrent SCLC cases. Higher efficiency in TP53 mediated PLK1 inhibition to control carcinoma. PLK1, a predictive biomarker for SCLC diagnosis. Market Summary Lung cancer...
Published: 12/6/2018       Inventor(s): Taofeek Owonikoko
DHAA and Derivatives for Treatment of BRAF-V600E-Positive Cancer
ApplicationHypolipidemic dehydroacetic acid (DHAA) treatment to prevent growth of BRAF V600E positive tumors.Key BenefitsTreatment with slows BRAF V600E-positive tumor growth.Repurposed compound may speed FDA approval.May be used in combination with other therapies.Market SummaryAccording to the American Cancer Society, skin cancer is the most common...
Published: 10/26/2017       Inventor(s): Jing Chen, Jack Arbiser, Brian Pollack, Siyuan Xia
Repurposed Kinase Inhibitor for Treatment of Multidrug Resistant Tuberculosis
ApplicationProtein tyrosine kinase inhibitor (imatinib) used as a treatment to prevent multiple drug-resistant tuberculosis lethality and latent reactivation.Key BenefitsEffective against drug resistant strains of tuberculosis.May be used in combination with current first-line treatments of TB.Market SummaryTuberculosis (TB) is a chronic infectious...
Published: 6/20/2017       Inventor(s): Daniel Kalman
Repurposed Small Molecules that Promote Osteogenesis
ApplicationRepurposed small molecules for use as a bone forming therapeutic during treatment of diseases requiring local bone formation such as fracture repair, spinal fusion, and large segmental bone defects. Key BenefitsCurrent treatments require high concentrations of bone morphogenetic protein (BMP) which results in high costs, adverse side effects,...
Published: 4/14/2016       Inventor(s): Scott Boden, Sreedhara Sangadala
Repurposed Small Molecules as a Targeted, Combination Therapy for Multiple Myeloma
ApplicationCombination of an inhibitor of glucose metabolism and BH3 mimetic for increased efficacy in the treatment of multiple myeloma.Key BenefitsActivates cell death pathways through independent molecular mechanisms, resulting in enhanced effect with combination therapy. Repurposed use of FDA-approved therapies to expand indications in oncology....
Published: 3/25/2016       Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai, Lawrence Boise
1 2